|
Aug 7
|
BC-Most Active Stocks
|
|
Aug 7
|
Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
|
|
Jul 31
|
Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
|
|
Jul 30
|
PALISADES ANNOUNCES CLOSING OF $8,251,800 LOAN WITH STRATEGIC INVESTOR
|
|
Jul 24
|
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
|
|
Jul 22
|
Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
|
|
Jul 22
|
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
|
|
May 27
|
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis
|
|
May 1
|
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit
|
|
Apr 9
|
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
|
|
Mar 14
|
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
|
|
Mar 12
|
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025
|
|
Feb 20
|
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)
|
|
Feb 19
|
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
|
|
Jan 3
|
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Sep 25
|
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
|
|
Jul 31
|
Palisade Bio Participates in Virtual Investor “What this Means” Segment
|
|
Jul 29
|
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108
|
|
Jun 24
|
Palisade Bio to Participate in the Virtual Investor Closing Bell Series
|
|
Jun 21
|
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
|